Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-01 11:00 |
Cantargia rapporterar positiva prekliniska effektdata för CAN10 som visar anti-…
|
Swedish | 234.4 KB | ||
| 2022-03-01 11:00 |
Cantargia reports positive preclinical efficacy data for CAN10 demonstrating an…
|
English | 228.0 KB | ||
| 2022-02-24 08:30 | Swedish | 704.0 KB | |||
| 2022-02-24 08:30 | English | 631.1 KB | |||
| 2022-02-22 15:00 |
Cantargia reports encouraging new CAN10 toxicology results and schedules phase …
|
English | 199.3 KB | ||
| 2022-02-22 15:00 |
Cantargia rapporterar nya lovande toxikologiresultat för CAN10 och planlägger f…
|
Swedish | 195.4 KB | ||
| 2022-02-04 09:00 |
Cantargia reports treatment of first non-squamous non-small cell lung cancer pa…
|
English | 198.7 KB | ||
| 2022-02-04 09:00 |
Cantargia rapporterar behandling av första patienten med icke-skivepitel icke-s…
|
Swedish | 199.8 KB | ||
| 2022-02-03 09:30 |
Cantargia reports positive safety data from CIRIFOUR clinical study on nadunoli…
|
English | 198.7 KB | ||
| 2022-02-03 09:30 |
Cantargia rapporterar positiva säkerhetsdata från kliniska studien CIRIFOUR med…
|
Swedish | 194.9 KB | ||
| 2022-01-19 14:30 |
Cantargia rapporterar överklagande av tredje part mot EPO:s beslut till förmån …
|
Swedish | 202.0 KB | ||
| 2022-01-19 14:30 |
Cantargia reports third party appeal against EPO decision in favor of Cantargia…
|
English | 197.0 KB | ||
| 2022-01-14 14:00 |
Cantargia reports treatment of first triple negative breast cancer patient in T…
|
English | 199.1 KB | ||
| 2022-01-14 14:00 |
Cantargia rapporterar behandling av första patienten med trippelnegativ bröstca…
|
Swedish | 197.9 KB | ||
| 2022-01-03 08:30 |
Cantargia tar nästa steg med nadunolimab mot bukspottkörtelcancer i PanCAN:s kl…
|
Swedish | 207.7 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
